A detailed history of China Universal Asset Management Co., Ltd. transactions in Merus N.V. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 11,113 shares of MRUS stock, worth $588,433. This represents 0.06% of its overall portfolio holdings.

Number of Shares
11,113
Previous 11,113 -0.0%
Holding current value
$588,433
Previous $500,000 -0.0%
% of portfolio
0.06%
Previous 0.06%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$28.03 - $51.82 $124,228 - $229,666
4,432 Added 66.34%
11,113 $500,000
Q4 2023

May 21, 2024

SELL
$20.06 - $28.66 $88,905 - $127,021
-4,432 Reduced 39.88%
6,681 $183,000
Q4 2023

Jan 23, 2024

BUY
$20.06 - $28.66 $104,392 - $149,146
5,204 Added 352.34%
6,681 $184,000
Q3 2023

May 21, 2024

BUY
$20.13 - $27.29 $17,452 - $23,660
867 Added 142.13%
1,477 $34,000
Q3 2023

Oct 30, 2023

BUY
$20.13 - $27.29 $17,452 - $23,660
867 Added 142.13%
1,477 $35,000
Q2 2023

May 21, 2024

SELL
$18.33 - $27.18 $329 - $489
-18 Reduced 2.87%
610 $16,000
Q2 2023

Jul 27, 2023

SELL
$18.33 - $27.18 $329 - $489
-18 Reduced 2.87%
610 $16,000
Q1 2023

May 21, 2024

BUY
$14.25 - $20.5 $2,237 - $3,218
157 Added 33.33%
628 $11,000
Q1 2023

Apr 27, 2023

BUY
$14.25 - $20.5 $2,237 - $3,218
157 Added 33.33%
628 $12,000
Q4 2022

May 21, 2024

SELL
$12.8 - $23.66 $136,217 - $251,789
-10,642 Reduced 95.76%
471 $7,000
Q4 2022

Jan 31, 2023

BUY
$12.8 - $23.66 $537 - $993
42 Added 9.79%
471 $7,000
Q3 2022

Oct 21, 2022

BUY
$18.64 - $28.93 $7,996 - $12,410
429 New
429 $9,000

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.43B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.